INTRODUCTION
S creening for Down's syndrome risk in the first trimester of pregnancy involves serum measurement of free beta human chorionic gonadotropin and pregnancy-associated plasma protein-A (PAPP-A), along with ultrasound measurement of nuchal translucency. 1, 2 Large multicentre trials in the USA 3 and Europe 4 have shown this combined testing to achieve an 85% Down's syndrome detection rate with an associated 5-6% falsepositive rate.
One of the barriers to implementing the combined test in the USA has been assay availability. PAPP-A immunoassay methods are in limited supply and no method has yet received clearance from the US Food and Drug Administration. One widely used method in the USA (Beckman Coulter Inc, Chaska, MN, USA, originally manufactured by Diagnostic Systems Labs Inc, Webster, TX, USA) is a manual enzyme-linked immunosorbent assay that is labour intensive and time consuming. The goal of this study was to evaluate a new automated method for PAPP-A measurement using the Beckman Coulter Access w platform. The analytical performance of this assay has been previously described. 5 We aimed to confirm and extend these findings by comparing Access w results with a method with widely proven Down's syndrome screening performance (PerkinElmer AutoDELFIA, Waltham, MA, USA). Specifically, we examined first trimester median PAPP-A levels using the Access w assay, the maternal weight effect, the distribution of PAPP-A values obtained with the Access w assay, and documented the well-described reduction in first trimester PAPP-A levels in a small group of women with Down's syndrome pregnancies.
METHODS
Residual serum samples were available as part of routine first trimester prenatal screening performed by the Division of Medical Screening and Special Testing at Women and Infants Hospital. Serum samples that had been collected between May and November 2007 were kept in freezer storage at 2208C. Samples from singleton pregnancies occurring in Caucasian women were eligible. Those reporting in vitro fertilization, or those with a known chromosomal abnormality were excluded. Approximately equal numbers of samples satisfying these criteria were randomly chosen within each week, except for 10 weeks, where fewer samples were available. A total of six samples from pregnancies affected by Down's syndrome were also available in the same gestational age range, but from a different time period (August 2007 through May 2009). This study was conducted with the approval of the Institutional Review Board for Human Studies at Women and Infants Hospital. A total of 416 samples were selected that covered the gestational age range of 10-13 completed weeks, as determined by crown rump length ultrasound measurements. Samples were retrieved from freezer storage and tested for PAPP-A using the automated Beckman Coulter (Access w ) method. A subset of these samples (n ¼ 194), covering the full range of results, were also run on the PerkinElmer AutoDELFIA (PE).
Method comparisons were performed by least-squares linear regression and Bland-Altman analyses 6 after appropriate logarithmic transformations. In order to compare the existing PAPP-A method, the values of which are expressed in mIU/mL, with those reported by Access w in ng/mL, a conversion factor specific to these kit lots/samples was calculated and applied. Access w PAPP-A results were regressed versus gestational age (in days) to generate medians. These were used to convert all results into multiple of the median (MoM) levels that were then weight-adjusted using a published reciprocal model. 7 The PAPP-A levels in the six Down's syndrome affected pregnancies were also converted to weight-adjusted MoM levels using the same medians and weight adjustment factors. The standard deviation (SD) for the first trimester PAPP-A weight-adjusted MoM levels (after a logarithmic transformation) was derived by computing the slope of the line fitted to the data in a probability plot over the range of values that appeared linear. This SD was then compared with others estimated in the literature for first trimester PAPP-A measurements. Tests of significance were two-sided, at a P 0.05 level. Graphics and select analyses were created using PRISM software (GraphPad, La Jolla, CA, USA). Additional analyses were performed using Excel (Microsoft, Redmond, OR, USA) or BMPD (Statistical Solutions, Saugus, MA, USA).
RESULTS

Method comparison
PAPP-A levels were compared between PE and Access w platforms. Since the PE assay is calibrated in mIU/mL while the Access w assay is calibrated in ng/mL, we created a 'conversion factor' so that comparisons could be on a common ng/mL scale. On average, 1 IU/mL was equivalent to 411 ng/mL (e.g. PE PAPP-A in mIU/mL Â 411 ¼ Access w PAPP-A in ng/mL). This conversion factor (411 ng/IU) was reasonably constant over the range of PAPP-A values. Figure 1a shows the scatterplot (on logarithmic scales) for the paired results. The correlation is 0.97 and the data appear close to the dashed line of equality. The Bland-Altman analysis ( Figure 1b ) shows a small but significant negative slope shown by the solid line (ratio ¼ 20.0734 Â average PAPP-A þ 0.2155, P , 0.001). On average, the Access w /PE ratio is 1.02 (Access w is 2% higher than PE) with the 95% prediction limits 8 of 0.75-1.40 indicated by dotted lines.
Medians and distribution of data
Median levels of PAPP-A by gestational age were calculated for the Access w assay (Table 1 ) using a log-linear regression analysis of value in ng/mL against gestational age in days (median PAPP-A value ¼ 10 (2.3109þ(days260)Â0.02306) ). Weighting was by the square root of the number of observations at each week. Assay results in ng/mL were then converted to MoM by dividing the day-specific median. The expected inverse relationship between PAPP-A MoM and maternal weight was observed ( Figure 2) . The PAPP-A MoM levels were then adjusted for maternal weight using a weighted reciprocal equation, fitted to the average maternal weight in pounds and associated median PAPP-A MoM levels, that best described the association (expected MoM ¼ (202.2508 Â 1/weight) 2 0.32681). The maternal weight adjustment included truncation limits of 100 and 250 pounds.
The distribution of PAPP-A MoM levels was compared with published distribution parameters as a means to verify reliable Down's syndrome risk assignment using the Access w assay method. Figure 3 shows the weight-adjusted PAPP-A MoM levels from the Access w platform on a probability plot, after a logarithmic transformation. A straight line indicates the data fit a log Gaussian distribution well. The slope of the line fitted to the data on that plot over the entire range of values provided a reliable estimate of the SD. The computed logarithmic SD is 0.2331. Table 2 contains published estimates of the PAPP-A log SD in unaffected pregnancies along with the estimate for the Access w platform derived in the present study. 2,4,9 -19 The Access w estimate is well within the published range, close to an estimate widely used when calculating Down's syndrome risk. 4 To examine Access w PAPP-A results in first trimester maternal serum from Down's syndrome pregnancies directly, residual serum was tested from six confirmed cases. The median level for the Access w assay was 0.30 MoM (range 0.10-1.50 MoM) in these samples. The median level reported for PAPP-A in Down's syndrome pregnancy ranges from 0.34 to 0.58 MoM. 4 These six data points (filled squares) have been included in Figure 3 for comparison with the levels found in unaffected pregnancies.
DISCUSSION
We have examined the Beckman Coulter Access w PAPP-A assay for use in the late first trimester of pregnancy. The Access w assay shows a high correlation with the Perkin Elmer PAPP-A assay which has proven to perform well in first trimester Down's syndrome screening. 4 Furthermore, the Access w results show the expected relationship with maternal weight, and PAPP-A MoM levels in first trimester unaffected pregnancies have an appropriate distribution, as shown by the probability plot and the SD of the log MoM. The current estimate of 0.2331 as the log SD is one of the reported estimates showing the lowest population variability. The low PAPP-A MoM level found in first trimester samples from women with Down's syndrome pregnancies provides further evidence for the suitability of this new platform. A separate study 5 concluded that the Access w assay for One other automated method for PAPP-A measurement, on the Immulite 2000 platform (Siemens Healthcare Diagnostics, Deerfield, IL, USA) has been available to some extent in the USA. Only one study has reported its performance in screening; the Immulite PAPP-A method was compared with the Brahms Kryptor platform (Annapolis, MD, USA, PAPP-A reagents not available in the USA) in 2005. 20 The Immulite was reported to have a high bias in cases leading to a PAPP-A median MoM of 0.62 in Down's syndrome, versus a median of 0.47 MoM using the Kryptor, suggesting a relative insensitivity for the Immulite method. Further study of the Immulite PAPP-A assay performance for Down's syndrome screening is required. In other studies, the Kryptor and PE assays were shown to give comparable results. 21 The absence of an international reference standard is a continuing issue in striving to improve uniformity of PAPP-A results between laboratories and methods. The Access w instrument calibrates PAPP-A levels in ng/mL 22 versus other methods that use mIU/mL as the reporting unit. Although disconcerting, this underscores the need for each prenatal screening laboratory to carefully monitor its median MoM levels over time regardless of the methodology chosen, and revise medians when necessary. A shared calibration material for PAPP-A assays would allow for more rigorous method comparisons and perhaps improve performance.
One strategy to understand the degree of agreement between laboratories that use PAPP-A measurement is interlaboratory proficiency programmes. One such programme exists in Europe (UK NEQAS, www.ukneqas.org.uk). Our group at Women and Infants Hospital (Providence, RI, USA) have recently introduced a similar Inter-laboratory Comparison Program for the USA and elsewhere (ICP, www.ipmms.org). 23 In the 2009 FT-C Survey, PAPP-A levels were reported by 26 participants using four different assay methods (Access w , DSL, PE, and Siemens Immulite). Among the five sample challenges, the coefficients of variation (CVs) for the 14 participants reporting in IU/mL and the 12 reporting in ng/mL were all 11% or lower, except for one sample with a very low target PAPP-A value. The corresponding MoM levels for the 24 clinical laboratories were combined into one analysis, with CVs for the five challenges ranging between 22% and 28%. These data suggest that continuing efforts need to be directed towards improving PAPP-A assay correspondence or agreement across platforms.
In summary, the Access w assay provides a simple and reliable method for the measurement of PAPP-A in pregnancy serum and is expected to give appropriate performance as a first trimester marker of Down's syndrome. Further progress in calibration and availability of PAPP-A assays, especially in the USA, would be helpful to laboratories interested in its clinical use.
